Literature DB >> 417410

Intensive surgical and chemotherapeutic management of advanced ovarian cancer.

C T Griffiths, A F Fuller.   

Abstract

We have presented the background and rationale for initiating a program of intensive surgical and chemotherapeutic management of advanced ovarian cancer. Our goal of excising all tumor masses larger than 1.5 cm in diameter has been explained and our operative approach described. The necessity for nutritional support has been emphasized. Preliminary results among patients with Stage III disease treated by optimal operation and Adriamycin-cyclophosphamide chemotherapy are encouraging. Aggressive operations have been unsuccessful when employed as secondary treatment. The single most important contraindication to extensive operation is the inability to initiate effective chemotherapy in the postoperative period.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 417410     DOI： 10.1016/s0039-6109(16)41440-4

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN： 0039-6109            Impact factor:   2.741


  18 in total

Review 1.  Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.

Authors:  Kazuaki Takahashi; Masataka Takenaka; Ayako Kawabata; Nozomu Yanaihara; Aikou Okamoto
Journal:  Int J Clin Oncol       Date:  2020-01-27       Impact factor: 3.402

2.  Treating ovarian cancer.

Authors:  R W Burslem; P M Wilkinson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-18

Review 3.  Primary metastatic breast cancer: the impact of locoregional therapy.

Authors:  Steffi Hartmann; Toralf Reimer; Bernd Gerber; Angrit Stachs
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

Review 4.  A framework for a personalized surgical approach to ovarian cancer.

Authors:  Alpa M Nick; Robert L Coleman; Pedro T Ramirez; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2015-02-24       Impact factor: 66.675

5.  Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.

Authors:  Shan Zhu; Chunliu Zhang; Dongyan Cao; Jing Bai; Shuangni Yu; Jie Chen; Jing Wang; Tong Ren; Jiaxin Yang; Mei Yu; Xiao Xiao; Yuhua Gong; Yanfang Guan; Peiling Li; Ying Yue; Rutie Yin; Yongjun Wang; Ruifang An; Ge Lou; Jianlin Yuan; Guonan Zhang; Xuefeng Xia; Ling Yang; Yang Xiang
Journal:  Oncogene       Date:  2022-04-25       Impact factor: 9.867

6.  Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Authors:  P Harter; S Mahner; F Hilpert; I Runnebaum; O Ortmann; A Mustea; J Sehouli; A du Bois; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

7.  Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.

Authors:  C F Verschraegen; S Kumagai; R Davidson; B Feig; P Mansfield; S J Lee; D S Maclean; W Hu; A R Khokhar; Z H Siddik
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-29       Impact factor: 4.553

8.  Recent progress in the treatment of epithelial ovarian malignancy.

Authors:  J S Berek; N F Hacker; L D Lagasse
Journal:  West J Med       Date:  1982-10

9.  When should surgical cytoreduction in advanced ovarian cancer take place?

Authors:  Igor E Martinek; Sean Kehoe
Journal:  J Oncol       Date:  2009-10-25       Impact factor: 4.375

10.  Metastatic disease to the breast: the Washington University experience.

Authors:  Aislinn Vaughan; Jill R Dietz; Jeffrey F Moley; Mary K Debenedetti; Rebecca L Aft; William E Gillanders; Timothy J Eberlein; Jon Ritter; Julie A Margenthaler
Journal:  World J Surg Oncol       Date:  2007-07-05       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.